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Available online xxxxBackground: Hypertrophic cardiomyopathy (HCM) is a common genetic heart disorder characterized by
unexplained left ventricle hypertrophy associated with non-dilated ventricular chambers. Several genes
encoding heart sarcomeric proteins have been associated to HCM, but a small proportion of HCM patients
harbor alterations in other non-sarcomeric loci. The variable expression of HCM seems influenced by genetic
modifier factors and new sequencing technologies are redefining the understanding of genotype–phenotype
relationships, even if the interpretations of the numerous identified variants pose several challenges.
Methods and results: We investigated 62 sarcomeric and non-sarcomeric genes in 41 HCM cases and in
3 HCM-related disorders patients. We employed an integrated approach that combines multiple tools for
the prediction, annotation and visualization of functional variants. Genotype–phenotype correlations
were carried out for inspecting the involvement of each gene in age onset and clinical variability of HCM. The
80% of the non-syndromic patients showed at least one rare non-synonymous variant (nsSNV) and among
them, 58% carried alterations in sarcomeric loci, 14% in desmosomal and 7% in other non-sarcomeric ones
without any sarcomere change. Statistical analyses revealed an inverse correlation between the number of
nsSNVs and age at onset, and a relationship between the clinical variability and number and type of variants.
Conclusions: Our results extend the mutational spectrum of HCM and contribute in defining the molecular
pathogenesis and inheritance pattern(s) of this condition. Besides, we delineate a specific procedure for the
identification of the most likely pathogenetic variants for a next generation sequencing approach embodied in
a clinical context.
© 2015 Elsevier B.V. All rights reserved.Keywords:
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Sarcomere1. Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder
with a 1/500 prevalence (Maron, 2002). It is a primary genetic
cardiomyopathy (Maron et al., 2006) characterized by a hypertrophicCM, dilatative cardiomyopathy;
ht ventricular cardiomyopathy;
s single nucleotide variant; ECG,
D, sudden cardiac death; NSVT,
rant from tolerant; PolyPhen-2,
tionary rate profiling; RMSD,
thickness; LVM, left ventricular
c defibrillator; PMK, pacemaker;
own clinical significance.
l., Molecular analysis of sar
.org/10.1016/j.gene.2015.11.0and non-dilated left ventricle in the absence of another systemic or
cardiac process that could reasonably account for the magnitude of
wall thickening. Heart muscle changes affect the electrical stability of
the myocardial cells, predisposing to heart failure and/or arrhythmias
(Dische, 1972). The HCM phenotype is highly variable, ranging from
lifelong absence of symptoms to rapidly progressive heart failure or
sudden cardiac death (Watkins et al., 1995). Two thirds of patients
display the left ventricular outflow tract obstruction strongly associated
with progression to severe symptoms of heart failure and of death
(Maron et al., 2003). Since the discovery of the first HCM-causing
gene (cardiac muscle β-myosin heavy chain, MYH7) (Jarcho et al.,
1989), a large number of mutations in other loci mostly encoding
sarcomeric proteins (i.e. ACTC1, FLNC, MYBPC3, MYH6, MYH7, MYL2,
MYL3, MYOM1, NEBL, TNNC1, TNNI3, TNNT2, TPM1) have been shown
to cause non-syndromic HCM (Marian et al., 2001; Arad et al., 2002;
Hershberger et al., 2013; Valdes-Mas et al., 2014). Sarcomeric alterationscomeric and non-sarcomeric genes in patients with hypertrophic
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2 I. Bottillo et al. / Gene xxx (2015) xxx–xxxare inherited as an autosomal dominant trait in about 50–60%of affected
adults. Besides, in a minor proportion of patients, mutations have been
also identified in several genes encoding Z-disk, cytoskeletal and other
non-sarcomeric proteins involved in Ca++ homeostasis, including
ANKRD1, CALR3, CAV3, CSRP3, DES, JPH2, MYLK2, MYOZ2, MYPN, NEXN,
PLN, TCAP and VCL (Millat et al., 2010). When occurring in the context
of a multisystemic disorder, hypertrophic cardiomyopathy may also
represent a relevant feature of non-sarcomeric gene syndromes com-
prising GLA (Fabry's disease, OMIM #301500), LAMP2 (Danon's disease,
OMIM #300257) and ABCC9 (Cantù syndrome, OMIM #239850).
Both HCM and other cardiomyopathies such as dilatative cardiomy-
opathy (DCM), restrictive cardiomyopathy (RCM), arrhythmogenic
right ventricular cardiomyopathy (ARVC), can be viewed as a continu-
um of phenotypes sharing typical symptoms of heart failure and
pathophysiological features (Frey et al., 2012). Furthermore, the cardio-
myopathies constitute an allelic series since they can be caused by
mutations at the same genes (Hershberger et al., 2013). Beyond their
substantial genetic overlap, only recently some genotype-phenotype
associations at a strong level of significance have been described.
Particularly for HCM, DNA variants in sarcomeric genes have been
associated with asymmetric septal hypertrophy pattern, younger age
at presentation, family history of the disease and sudden cardiac
death, greater maximum left ventricle wall thickness and an increased
incidence of cardiovascular death (Lopes et al., 2014). Although etiology
identificationmay be important for screening of at risk familymembers,
cardiomyopathy molecular diagnosis is still difficult due to the large
number of causative genes and the high rate of private mutations.
Next generation sequencing (NGS) results in a remarkable increase in
speed and efficiency, transforming our insights about rare-variant
genomic diseases, and over the past decade, many bioinformatics
algorithms have been developed to predict functional consequences of
single nucleotide variants in coding regions.
The aim of this study was to explore the role in HCM onset and
expression of 62 sarcomeric and non-sarcomeric genes in 41 patients
with hypertrophic cardiomyopathy and 3 cases affected by a HCM-
related disorder. Each identified rare (frequency ≤0.01) non-
synonymous Single Nucleotide Variant (nsSNV) was firstly validated
by Sanger sequencing.We also adopted a comprehensive computation-
al schema for variants's annotation and predictions, in order to improve
genomic reports generated from the experimental studies, and to
better understand the variations implicated in HCM manifestations.
Genotype–phenotype correlations were finally carried out for
outlining the contribution of each analyzed gene in the onset and
clinical variability of HCM.
2. Materials and methods
2.1. Patients
Patients were selected from those attending an outpatient
hospital service dedicated to the diagnosis and management of
HCM. All patients underwent clinical history registration, physical
examination, electrocardiography (ECG), echocardiography, cardiopul-
monary exercise test coupled with ambulatory ECG monitoring.
Thirty-two out of 44 patients were evaluated by cardiac magnetic
resonance (CMRI). Diagnostic criteria for HCM was defined in adults
by amaximal left ventricular wall thickness ≥ 13mmon echocardiogra-
phy, in the absence of other loading conditions (Klues et al., 1995).
Family history of Sudden Cardiac Death (SCD), syncope episodes and
the presence of Non-Sustained Ventricular Tachycardia (NSVT) were
defined as described by O'Mahony et al. (2014). Electrocardiographic
changes that were considered of clinical significance included abnormal
Q waves (0.04 s or 25% depth of an R-wave), LVH (voltage criteria),
and marked repolarization changes (e.g. T-wave inversion in at least
2 leads). The QT interval corrected for heart rate was calculated using
the Bazett's formula (QTc (ms) = QT / √RR, where RR is the RR intervalPlease cite this article as: Bottillo, I., et al., Molecular analysis of sar
cardiomyopathy, Gene (2015), http://dx.doi.org/10.1016/j.gene.2015.11.0measured in seconds). Familial HCM cases were defined if at least one
additional affected family member with HCM, or one case of sudden
cardiac death was present in the pedigree. All patients gave informed
consent for the DNA analyses, which was approved by local ethic
committees in accordance with the principles of the Declaration
of Helsinki.
2.2. Next generation sequencing (NGS)
Genomic DNA from peripheral blood was tested by NGS with a
custom design for the cardiomyopathy panel, based on AmpliSeq
strategy (ThermoFisher, Carlsbad, CA, USA). The panel was designed
to analyze coding, intronic junctions and UTR sequences of 62 genes.
Those comprised 12 sarcomeric loci (ACTC1, MYBPC3, MYH6, MYH7,
MYL2,MYL3,MYOM1, NEBL, TNNC1, TNNI3, TNNT2, TPM1), 9 cytoskeletal
(CRYAB, DES, DMD, DTNA, EMD, FXN, LAMA4, PDLIM3, SGCD), 9 Z-disk
(ACTN2, ANKRD1, CSRP3, LDB3, MYOZ2, MYPN, NEXN, TCAP, VCL),
6 desmosomal (DSC2, DSG2, DSP, FHL2, JUP, PKP2), 5 intracellular
Ca++ homeostasis (CALR3, CASQ2, JPH2, PLN, RYR2), 3 genes encoding
for K+ and Na+ channels and interacting proteins (ABCC9, CAV3,
SCN5A) and 18 other non-sarcomeric loci (BAG3, CTF1, EYA4, GATAD1,
GLA, ILK, LAMP2, LMNA, MYLK2, PRKAG2, PTPN11, RAF1, RBM20, TAZ,
TMEM43, TMPO, TTR, TXNRD2).
In summary, the panel included 36 genes known to be associated
with HCM and dilated cardiomyopathy (ACTC1, ACTN2, ANKRD1, BAG3,
CALR3, CAV3, CRYAB, CSRP3, DES, EYA4, GATAD1, ILK, JPH2, LAMA4,
LDB3, LMNA, MYBPC3, MYH6, MYH7, MYL2, MYL3, MYLK2, MYOZ2,
MYPN, NEXN, PDLIM3, PLN, RBM20, SGCD, TCAP, TMPO, TNNC1, TNNI3,
TNNT2, TPM1 and VCL), 7 genes related with arrhythmogenic right
ventricular cardiomyopathy and left ventricular non-compaction
(DSC2, DSG2, DSP, DTNA, JUP, PKP2 and TMEM43), 7 genes associated
to malformation syndromes and storage disorders (ABCC9, GLA, LAMP2,
PTPN11, PRKAG2, RAF1 and TTR), 4 genes related to myopathies and
neuromuscular disorders (DMD, EMD, FXN and TAZ), 3 genes implicated
in arrhythmia syndromes/ion-channel disease (CASQ2, RYR2 and
SCN5A) and other 5 cardiovascular candidate genes (CTF1, FHL2,
MYOM1, NEBL and TXNRD2).
Supplementary Table 1 summarizes the genes included in the study
as well as their function, associated disorder(s), chromosomal position
and sequencing details. The design allowed the targeted resequencing
of 2890 amplicons (global size: 345,39 kb/patient) by Ion Torrent
PGM instrument (ThermoFisher, Carlsbad, CA, USA). In order to validate
the appliedNGSprotocol the entire coding sequences ofMYH7,MYBPC3,
TNNT2 and TNNI3 genes of 23/44 patients were at first analyzed by
Sanger sequencing.
2.3. Analysis of raw NGS data
The NGS read depth of each analysed gene is shown in Fig. S1. The
genes included in the NGS panel, as well as their function within the
cell, associated disorder(s), chromosomal location and sequencing
details are shown in Supplementary Table 1. The total number and
type of DNA point variants identified for each patient is given in Sup-
plementary Table 2. For each patient, the summary of clinical and
molecular data is tabulated in Supplementary Table 3. The synony-
mous variants identified for each patient are given in Supplementary
Table 4.
2.4. Variant calling, annotation and prioritization
Variant calls were annotated by wANNOVAR Web Server
(wannovar2.usc.edu/). The nucleotide variants with a Minor Allele
Frequency (MAF) ≤0.01 both in the 1000 Genome Project (global
and European) and in the NHLBI-ESP 6500 exome project (global)
were filtered and designed as “rare variants”. Between the selected
variants, only the exonic and ±10 bp intronic ones were prioritizedcomeric and non-sarcomeric genes in patients with hypertrophic
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3I. Bottillo et al. / Gene xxx (2015) xxx–xxxand validated by Sanger sequencing. The confirmed DNA changes
were subjected to different in silico predictions by the following
methods: SIFT, PolyPhen-2_HDIV, PolyPhen-2_HVAR, Provean, LRT,
Mutation Taster, Mutation Assessor, FATHMM, RadialSVM, LRT,
CADD v1.3 and molecular modeling, for the analysis of missense
variants; Human Splicing Finder (HSF) 3.0, for the analysis of intronic
changes; GERP++, PhyloP placental, PhyloP vertebrate and SiPhy,
for exploring nucleotide-specific estimates of evolutionary constraint
(Bottillo et al., 2015).2.5. Statistical assessment of genotype–phenotype correlations
All statistical analyses were performed using SPSS (statistical
software package version 20.0). For each patient, the clinical data and
molecular data (i.e. total number nsSNVs, number of any class of
nsSNVs) were tabulated (Supplementary Table 3).
Phenotype data were presented as continuous variables obtained
from clinical data and instrumental measurements. Categorical
variables were shown as the presence/absence or grade, of the clinical
feature. Continuous variables were summarized using means and
standard deviations, while categorical variables were summarized
using frequencies and percentages.
The molecular data were presented as number of DNA rare
(frequency ≤0.01) nsSNVs variants identified in each functional class.
The genes carrying rare variants were indeed grouped into sarcomeric,
desmosomal, K+ and Na+ channels and interacting proteins, loci for
mRNA splicing and cellular enzymes, cytoskeletal, Z-disk and Ca++
homeostasis.
Statistical correlations for non-syndromic patients were evaluated
between the presence of rare DNA variants (or the family history) and
the prevalence of phenotypic traits with the following methods:
(i) Chi-square test when referred to categorical variables; (ii) unpaired
two-tailed Student's t-test when related to continuous variable. Due to
the relatively low number of patients no adjustments was planned for
multiple testing; the analysis is therefore exploratory and results to be
considered as hypotheses-generating.3. Results
3.1. Phenotype analysis
Forty-four unrelated Caucasian/Italian patients (23 males and
21 females) were included in this study. Three patients displayed
HCM associated with a syndromic phenotype: case 10, 24 and 27
were respectively affected by a mild form of Fabry's disease, by
Cantù's syndrome and by Danon's disease. Supplementary Table 3
summarizes the clinical features of the patients at evaluation.3.2. Genotyping results
Among the 41 non-syndromic HCM cases, 33 (80%) were found
to carry at least one rare nsSNV. In total, 95 non-synonymous
sequence changes, of which 87 different, were identified. These
included 73 missense, 13 intronic, 3 frameshift, 4 nonsense, one
stop-loss and one in frame deletion. Among the 87 different nsSNVs,
21 were already reported in literature (Table 1).
The proportion of nsSNVs identified for each analyzed gene is shown
in Fig. 1a.
About 33% of the changes mapped in sarcomeric loci, 19% in
desmosomal loci, 15% in genes coding for K+ and Na+ channels and
for channels-interacting proteins, 12% in genes coding for mRNA
splicing and other cellular enzymes, 9% in cytoskeletal loci, 6% in
genes related to intracellular Ca++ homeostasis, 5% in Z-disk loci
and 5% in other non-sarcomeric loci (Fig. 1b).Please cite this article as: Bottillo, I., et al., Molecular analysis of sar
cardiomyopathy, Gene (2015), http://dx.doi.org/10.1016/j.gene.2015.11.0The 27% of the patients harbored two heterozygous DNA changes in
different genes, 15% a single heterozygous change and 39% three or
more variants (Fig. 1c).
Twenty-four/41 of the cases harbored at least one sarcomeric nsSNV,
and three patients carried only desmosomal changes. In total, 58%
carried alterations in sarcomeric loci, 14% in desmosomal and 7% in
other non-sarcomeric ones without any sarcomere change. Fig. 1d
illustrates the fraction of mutated cases respect to the different
genes' categories.
Among the syndromic patients, case 10 was found to carry the
p.N215S mutation in the GLA gene, previously associated with a
mild form of Fabry disease (Davies et al., 1993; Eng et al., 1993),
case 24 harbored the ABCC9 p.R1154W mutation causing Cantù's
syndrome (Harakalova et al., 2012; van Bon et al., 2012) and case
27 carried the novel LAMP2 p.F151fs mutation. In addition, they
were found to carry other rare nsSNVs (Table 1).
Themolecular analyses also identified 49 heterozygous synonymous
variants, of which 36 different, that are reported in Supplementary
Table 4.
3.3. In silico predictions
Twelve methods were employed for assessing the possible
pathogenicity of the identified missense changes (see Table 1 in
(Bottillo et al., 2015)). The variants with at least 6/12 deleterious
predictions have been considered possibly pathogenetic, while a
“no predicted deleterious effect” was accounted for those scored
with two or less deleterious predictions (Table 1). The in silico
scores were completely concordant for 20 variants (14 benign and
6 deleterious), but ambiguous for 19 changes which resulted in 3 to
5 deleterious predictions among 12 ones
Nine among the 14 different intronic variantswere predicted to alter
a splicing site.
Among the 85 different nsSNVs identified in this study, 24
resulted in the alteration of an allele that is highly conserved across
evolutionarily distant species (Table 1). For those DNA changes,
the four computational methods employed for the nucleotides'
conservation analysis gave concordant scores (see Table 1 in Bottillo
et al. (2015)).
Inferring from the type of the variant, querying of frequency and
mutational databases, as well as from the output of in silico predictions,
all but three (patient 3, 37 and 52) mutated cases harbored at least one
non-synonymous DNA change predicted to be pathogenetic, or already
reported as disease-modifying factor (Table 1).
3.4. Genotype–phenotype correlations
We observed an inverse correlation between the age at diagnosis
and the total number of nsSNVs: the mean age at diagnosis was indeed
60 years in the groupwithout variants and 43.8 years in the group with
variants (P = 0.01).
The presence of nsSNVS in the genes involved in intracellular
Ca++ homeostasis was significantly correlated to an earlier HCM
onset: the mean age at diagnosis was in fact 35.8 years between
the cases carrying those variants, versus 48.2 years in the cases
without them (P = 0.03).
The mean value of maximum wall thickness was lower both in the
group carrying nsSNVs in genes for K+ and Na+ channels (P = 0.03),
and in the group not harboring variants for Ca++ homeostasis (P =
0.05). Moreover we observed a correlation between maximum wall
thickness and the family history, as the mean of the MWT value of
was lower in the sporadic group (18.055 mm) than in the familial
group (22.3 mm) (P = 0.05).
The occurrence of non-synonymous changes in cytoskeletal loci
was correlated with the presence of non-sustained ventricular
tachycardia: NSTV was indeed present in 40% of the patientscomeric and non-sarcomeric genes in patients with hypertrophic
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Table 1
Rare nsSNVs identified in 36/44 HCMpatients. A comment inferred from review of literature, in silico predictions and evolution conservation analysis, is given for each DNA change in the
last column. Based on those considerations and on the type of variant, comments with a gray background highlight DNA changes predicted to be possibly pathogenetic. Comments in bold
stand for DNA variants that have been previously reported as phenotype modifying factors.
Pt Gene Mutation Status 1000GALL
1000G
EUR
ESP6500si
ALL Type
ClinVar
SIG Reference Comment
1
MYBPC3 c.T1664C,p.M555T Htz – – – missense unk Girolami et al. 2006 No predicted deleterious effect
RyR2 c.A3380G,p.E1127G Htz 0.0006 – 0.0006 missense unk –
8/12 deleterious predictions
The reference allele is conserved across 
evolutionarily distant species
3 TMPO c.A1037G,p.H346R Htz 0.0002 – – missense – – No predicted deleterious effect
5 MYH6 c.643–5C>T Htz – – 0.0005 intronic unk|PnPath – Branch–point splice site broken
8
RBM20 c.G3373A,p.E1125K Htz 0.002 0.007 0.0037 missense PnPath – Ambiguous in silico predictions  
MYH6 c.2928+5G>A Htz 0.0002 0.001 0.0018 intronic PnPath – Donor splice site broken
CSRP3 c.T10C,p.W4R Htz 0.0018 0.005 0.0037 missense unk|PnPath Knoll et al. 2002Geier et al. 2008
6/12 deleterious predictions
Previously reported alone in CMD1M 
patients and in conjunction with a 
sarcomeric mutation in HCM patients
The reference allele is conserved across 
evolutionarily distant species
LAMA4 c.A4937G,p.E1646G Htz – – 0.0001 missense – –
11/12 deleterious predictions
The reference allele is conserved across 
evolutionarily distant species
LAMA4 c.G1565C,p.R522T Htz – – – missense – – No predicted deleterious effect
9
MYBPC3 c.A3825C,p.*1275Cysext*33 Htz – – – stop loss unk – Stop loss
NEBL c.G604A,p.G202R Htz 0.0014 0.003 0.0018 missense – Purevjav et al. 2010
Previously identified in one DCM individual. 
The Gly202Arg mouse model exhibits DCM 
features
RyR2 c.9450–9C>T Htz – – – intronic – – No predicted deleterious effect
10*
MYBPC3 c.C1112A,p.P371Q Htz – – – missense Path –
8/12 deleterious predictions
The reference allele is conserved across 
evolutionarily distant species
GLA c.A644G,p.N215S Htz – – – missense – Eng et al. 1993Davies et al. 1993
9/12 deleterious pr edictions
Previously associated with a mild forms of 
Fabry disease
The reference allele is conserved across 
evolutionarily distant species
DSP c.G137A,p.G46D Htz – – 0.0001 missense – – No predicted deleterious effect
TXNRD2 c.G1150A,p.G384S Htz 0.0018 0.006 0.0041 missense – Sibbing et al. 2011 Ambiguous in silico predictions 
11
JPH2 c.G1536C,p.W512C Htz – – – missense – – Ambiguous in silico predictions 
SCN5A c.A5605T,p.I1869F Htz – – – missense PnPath – 12/12 deleterious predictions
FHL2 c.G109T,p.A37S Htz 0.0016 – 0.0023 missense unk – Ambiguous in silico predictions 
DSC2 c.C1787T,p.A596V Htz 0.0022 0.002 0.0009 missense PnPath den Haan et al. 2009
Ambiguous in silico predictions 
Previously reported in one individual with 
ARVC
The reference allele is conserved across 
evolutionarily distant species
14 PKP2 c.G76A,p.D26N Htz 0.003 0.011 0.0049 missense – Christensen et al. 2010
6/12 deleterious predictions
Previously reported as modifier of disease, 
over–represented  in ARVC cases
15 MYOM1 c.C2131T,p.R711C Htz – – 0.0001 missense – – 11/12 deleterious predictionsRAF1 c.[124G>A;125C>T] p.A42I Htz – – – missense – – Ambiguous in silico predictions 
17
TNNT2 c.A252T,p.R84S Htz – – – missense unk –
10/12 deleterious predictions
Previously identified in one Asian HCM 
individual
MYOM1 c.4485–6T>C Htz intronic – – Branch–point splice site broken
RBM20 c.A59G,p.D20G Htz – – – missense – – Ambiguous in silico predictions 
CAV3 c.C233T,p.T78M Htz 0.002 0.005 0.0043 missense untested
Fulizio et al. 2005
Vatta et al 2006
Cronk et al 2007
8/12 deleterious predictions
Previously found in 3 unrelated individuals 
with long QT syndrome. The mutant causes a 
5–fold increase in late sodium current 
compared to wild–type
18
DSG2 c.A208G,p.I70V Htz – – – missense – – No predicted deleterious effect
DSP c.G5218A,p.E1740K Htz 0.0004 0.002 0.0009 missense unk Cox et al. 2011
Ambiguous in silico predictions 
Previously reported in two  ARVC 
individuals; both individuals carried a second
likely pathogenic variant
19
DSP c.4441_4443del,p.K1481_1481del Htz in frame del – – In frame deletion
MYOM1 c.G2132A,p.R711H Htz 0.0002 – – missense Ppath –
11/12 deleterious predictions
The reference allele is conserved across 
evolutionarily distant species
SCN5A c.C5837T,p.S1946F Htz – – – missense – Hermida JS 2010
7/12 deleterious predictions
Reported as “probably pathogenetic” in 
ClinVar database
DSC2 c.C2328G,p.I776M Htz – – 0.0001 missense – – No predicted deleterious effect
LAMA4 c.T3482C,p.M1161T Htz – – – missense – – No predicted deleterious effect
LAMP2 c.C418G,p.L140V Hem – – – missense – – No predicted deleterious effect
20 DSG2 c.G2147A,p.G716E Htz – – – missense nPath – No predicted deleterious effect
LAMA4 c.4665+8G>T Htz 0.0004 – 0.0016 intronic other|Path – IIE site splice broken 
21
MYBPC3 c.2309–2A>G Htz – – – intronic – Van Driest 2004Roncarati 2011
Acceptor splice site broken
Reported as “pathogenetic” in ClinVar 
database
RyR2 c.G1454A,p.R485Q Htz – – – missense PPath|nPath –
10/12 deleteri ous predictions
The reference allele is conserved across 
evolutionarily distant species
ABCC9 c.G2200A,p.V734I Hmz 0.004 0.014 0.0092 missense – Minoretti et al. 2006
Ambiguous in silico predictions
Previously reported as influencing 
susceptibility to precocious myocardial 
infarction
CALR3 c.A1036G,p.I346V Htz – – – missense PnPath|other – No predicted deleterious effect
TNNT2 c.264+7G>A Htz 0.01 – 0.011 intronic – Kassem et al 2013 Donor splice site broken. It is a common 
variant in the Black population
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The reference allele is conserved across 
evolutionarily distant species
ILK c.G1086C,p.Q362H Htz – – 0.0001 missense unk – 11/12 deleterious predictions
23
DSC2 c.C1787T,p.A596V Htz 0.0022 0.002 0.0009 missense – den Haan et al. 2009
Ambiguous in silico predictions  
Previously reported in one individual with ARVC 
The reference allele is conserved across 
evolutionarily distant species
LAMA4 c.G1967A,p.S656N Htz – – – missense – – No predicted deleterious effect
MYH6 c.G68A,p.R23H Htz – – – missense – –
11/12 deleterious predictions
The reference allele is conserved across 
evolutionarily distant species
TPM1 c.C134T,p.A45V Htz – – – missense unk|unk –
9/12 deleterious predictions
The reference allele is conserved across 
evolutionarily distant species
24*
PKP2 c.C2299A,p.R767S Htz 0.0006 0.002 0.0004 missense Path|other
Fressart 2010
Klauke 2010
Tan 2010
6/12 deleterious predictions
Previously identified in 4 ARVC, one HCM, and
one VT patients
DSP c.G88A,p.V30M Htz 0.0022 0.001 0.0012 missense – Yang et al. 2006
Previously found in one ARVC patient. The 
mutant allele fails to localize to the cell 
membrane in a desmosome–forming cell line 
and fails to bind to and coimmunoprecipitate 
junction plakoglobin
RyR2 c.A4273G,p.T1425A Htz – – – missense – –
Ambiguous in silico predictions 
The reference allele is conserved across 
evolutionarily distant species
MYBPC3 c.821+3G>A Htz intronic Path – IIE splice site broken
ABCC9 c.C3460T,p.R1154W Htz – – – missense – van Bon 2012Harakalova 2012
11/12 deleterious predictions
Reported as “pathogenetic” in ClinVar database 
Causes Cantù syndrome
25
MYBPC3 c.2846dupT,p.M949fs Htz – – – frameshift unk|PnPath – Truncating mutation
TXNRD2 c.375–8C>T Htz 0.0004 – 0.0007 intronic PnPath – No predicted deleterious effect
CSRP3 c.T10C,p.W4R Htz 0.0018 0.005 0.0037 missense unk Knoll et al. 2002Geier et al. 2008
Previously reported alone in CMD1M  
patients and in conjunction with a
sarcomeric mutation in HCM patients
RBM20 c.G3373A,p.E1125K Htz 0.002 0.007 0.0037 missense unk – Ambiguous in silico predictions 
26
DSP c.C3956T,p.T1319I Htz – – 0.0001 missense untested –
8/12 deleterious predictions
The reference allele is conserved across 
evolutionarily distant species
ABCC9 c.2238–1G>A Htz 0.0018 0.001 0.0008 intronic other|Path –
Acceptor splice site broken
The reference allele is conserved across 
evolutionarily distant species
CAV3 c.C233T,p.T78M Htz 0.002 0.005 0.0043 missense –
Fulizio et al. 2005
Vatta et al 2006
Cronk et al 2007
8/12 deleterious predictions
Previously found in 3 unrelated individuals 
with long QT syndrome. The mutant causes a 
5–fold increase in late sodium current 
compared to wild–type
MYBPC3 c.2309–2A>G Htz – – – intronic – – Acceptor splice site broken
Reported as “pathogenetic” in ClinVar database
DTNA c.C2095T,p.R699C Htz missense PnPath – No predicted deleterious effect
27* LMNA c.1363–7T>C Htz intronic unk|unk – No predicted deleterious eff ectLAMP2 c.453delT,p.F151fs Hem frameshift Path|nPath – Truncating mutation
29 ABCC9 c.816+11G>A Htz 0.0004 0.001 0.0002 intronic unk|PnPath|nPath – Donor splice site broken
31
PKP2 c.C2299A,p.R767S Htz 0.0006 0.002 0.0004 missense –
Fressart 2010
Klauke 2010
Tan 2010
6/12 deleterious predictions
Previously identified in 4 ARVC, one HCM, and
one VT patients
JPH2 c.G1513A,p.G505S Htz 0.015 0.011 0.0071 missense – Matsushita 2007Bean 2013
Previously identified in 4 Japanese HCM 
probands 
MYBPC3 c.3192dupC,p.K1065fs Htz – – – frameshift –
Girolami 2006
Girolami 2010
Olivotto 2011
Truncating mutation
32
JUP c.909+6C>T Htz – – 0.0014 intronic – – No predicted deleterious effect
RAF1 c.G1858A,p.A620T Htz – – – missense PnPath –
6/12 deleterious pre dictions
The reference allele is conserved across  
evolutionarily distant species
SCN5A c.C1810G,p.L604V Htz – – – missense unk|PPath – Ambiguous in silico predictions 
33 PDLIM3 c.G163T,p.E55X Htz – – – nonsense – – Truncating mutationMYBPC3 c.C3775T,p.Q1259X Htz – – – nonsense PnPath – Truncating mutation
34
ABCC9 c.2867–5T>C Htz – – 0.0001 intronic untested|Path|PnPath – No predicted deleterious effect
MYOM1 c.T199G,p.S67A Htz – – 0.0001 missense – – No predicted deleterious effect
PKP2 c.G76A,p.D26N Htz 0.003 0.011 0.0049 missense – Christensen et al. 2010
6/12 deleterious predictions
Previously reported as modifier of disease, 
over–represented  inARVC cases
TNNT2 c.A755T,p.K252I Htz – – – missense – –
11/12 deleterious predictions
Reported as “probably pathogenetic” in 
ClinVar database
SCN5A c.G2614A,p.D872N Htz – – – missense – – 6/12 deleterious predictions
BAG3 c.G463A,p.A155T Htz 0.0018 0.008 – missense untested – No predicted deleterious effect
35
MYPN c.C3335T,p.P1112L Htz 0.0026 0.005 0.0021 missense PPath|Path
Duboscq–Bidot 2007
Adzhubei 2010
Purevjav  2012
7/12 deleterious predictions
Previously reported in HCM and DCM patients
The reference allele is conserved across 
evolutionarily distant species
CAV3 c.G221A,p.R74H Htz 0.0002 – – missense PnPath El Huneidi 2014
11/12 deleterious predictions
The reference allele is conserved across 
evolutionarily distant species
36 MYH7 c.G676A,p.A226T Htz – – – missense – – 9/12 deleterious predictions
37 DSP c.G6188A,p.R2063Q Htz – – 0.0001 missense unk – Ambiguous in silico predictions 
DSC2 c.C595T,p.R199C Htz – – – missense PnPath – Ambiguous in silico predictions 
22 MYH7 c.4402G>A,p.E1468K Htz – – – missense – – 9/12 deleterious predictions
Table 1 (continued)
(continued on next page)
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evolutionarily distant species
43 MYH6 c.G622A,p.D208N Htz 0.002 0.005 0.0049 missense other|Path Granados–Riveron et al. 2010 No predicted deleterious effectMYBPC3 c.C1302A,p.Y434X Htz – – – nonsense PnPath – Truncating mutation
44
MYH6 c.G4193A,p.R1398Q Htz – – 0.0001 missense – –
7/12 deleterious predictions
The reference allele is conserved across 
evolutionarily distant species
DSG2 c.G2033C,p.G678A Htz – – 0.0002 missense nPath – No predicted deleterious effect
PKP2 c.C1445T,p.T482M Htz 0.0038 0.005 0.0037 missense unk – No predicted deleterious effect
MYH7 c.G428A,p.R143Q Htz – – – missense unk
Song 2005
Van Driest 2004
Wang 2007
Kimura 2010
Gruner 2011
Fokstuen 2011
9/12 deleterious predictions
Previously reported in 6 HCM individuals
The reference allele is conserved across 
evolutionarily distant species
45
MYBPC3 c.A649G,p.S217G Htz 0.0018 0.001 0.001 missense unk Lakdawala et al. 2012 Ambiguous in silico predictionsLikely benign when present in isolation
MYH7 c.C2167T,p.R723C Htz – – – missense unk|PnPath
Watkins 1992
Tesson 1998
Richard 2003
Ingles 2005
Girolami 2010
10/12 deleterious predictions
Previously reported in 5 HCM families
Residue 723 is conserved among all known 
cardiac MHCs and all vertebrate striated 
muscle MHCs except the human perinatal and 
rabbit skeletal isoforms
Mutation to a Cys changes Thr net charge
46 MYBPC3 c.3192dupC,p.K1065fs Htz – – – frameshift –
Girolami 2006
Girolami 2010
Olivotto 2011
Truncating mutation
49
RBM20 c.G3373A,p.E1125K Htz 0.002 0.007 0.0037 missense – – Ambiguous in silico predictions 
DSP c.C5851T,p.R1951X Htz – – – nonsense ClinVar_SIG – Truncating mutation
TMPO c.G1696A,p.D566N Htz – – – missense unk – Ambiguous in silico predictions 
MYL2 c.G34T,p.G12C Htz – – – missense unk –
7/12 deleterious predictions
The reference allele is conserved across 
evolutionarily distant species
51 VCL c.A1907G,p.H636R Htz 0.0004 0.001 0.0009 missense – Zimmerman 2010
9/12 deleterious predictions
Detected in 1/>250 Caucasian DCM 
individuals and in another DCM proband of 
unknown ethnicity
The reference allele is conserved across 
evolutionarily distant species
MYBPC3 c.T1664C,p.M555T Htz – – – missense unk|PnPath Girolami et al. 2006 No predicted deleterious effect
52
ACTN2 c.C1484T,p.T495M Htz – – 0.0001 missense PnPath
Ambiguous in silico predictions 
The reference allele is conserved across 
evolutionarily distant species
SCN5A c.C2074A,p.Q692K Htz 0.0002 0.001 0.0002 missense PnPath Van Langen 2003Ackerman 2004 Ambiguous in silico predictions 
DMD c.G1646A,p.R549Q Hem – – – missense unk|PnPath –
Ambiguous in silico predictions 
The reference allele is conserved across 
evolutionarily distant species
DMD c.C3164T,p.T1055I Hem – – – missense – – No predicted deleterious effect
38
CAV3 c.C233T,p.T78M Htz 0.002 0.005 0.0043 missense other|Path
Fulizio et al. 2005
Vatta et al 2006
Cronk et al 2007
8/12 deleterious predictions
Previously found in 3 unrelated individuals 
with long QT syndrome. The mutant causes a 
5–fold increase in late sodium current 
compared to wild–type
MYH7 c.G3346A,p.E1116K Htz – – – missense PnPath|unk –
10/12 deleterious predict ions
Reported as “pathogenetic” in ClinVar database
The reference allele is conserved across 
Based on Table 1 inBottillo et al. (2015),missense changeswith at least 6/12deleterious in silico predictionshavebeen considered “risk variants”possibly pathogenetic (gray background).
Nucleotides highly conserved across evolutionarily distant species are those for which all the conservation analyses were concordant.
Pt: patient; 1000G ALL: MAF in 1000 Genomes Project global; 1000G EUR: MAF in 1000 Genomes Project European; ESP6500si ALL: MAF in exome sequencing project global; Htz:
heterozygosity; Hem: hemizygosity; Hmz: homozygosity; ClinVar SIG: significance in ClinVar database, including unknown (unk), non-pathogenic (nPath), probable-non-pathogenic
(PnPath), probable-pathogenic (PPath), pathogenic (Path); HCM: hypertrophic cardiomyopathy; DCM: dilated cardiomyopathy; CMD1M: cardiomyopathy, dilated, 1 M; ARVC:
arrhythmogenic right ventricular cardiomyopathy; IIE: intron identity element; VT: ventricular tachycardia;MHC: myosin heavy chain.
⁎ Syndromic patients.
Table 1 (continued)
6 I. Bottillo et al. / Gene xxx (2015) xxx–xxxcarrying cytoskeletal nsSNVs, versus 11% of patients not carrying
them (P = 0.05). NSTV was also correlated with familial cases,
respect to sporadic ones (P = 0.02).
Cytoskeletal variants were correlated with a minor grade (grade
0–1) of diastolic dysfunction (P = 0.004) and, regarding New York
Heart Association (NYHA) functional classification, sarcomeric
variants were present in all grade I (no limitation of physical
activity), in 56% of grade II (slight limitation of physical activity),
and in 33% of grade III (marked limitation of physical activity)
patients (P = 0.05).
The prevalence of male sex was higher, respect to female in the
group carrying at least one nsSNV compared with the HCM patients
with no rare nsSNV (P = 0.01).
Finally we identified a statistically significant correlation between
the presence of an implantable cardioverter-defibrillator and familyPlease cite this article as: Bottillo, I., et al., Molecular analysis of sar
cardiomyopathy, Gene (2015), http://dx.doi.org/10.1016/j.gene.2015.11.0history (P = 0.03): the implantation of ICD resulted to be linked to a
familial framework.4. Discussion
Here we present a NGS analysis of the prevalence of sarcomeric
and non-sarcomeric gene variants in 41 patients affected by primary
hypertrophic cardiomyopathy, and in 3 cases affected by syndromic
HCM. This study was aimed the discovery of disease causing genetic
variation for an appropriate genetic counseling, as well as for the
enlargement of theHCMmutational spectrum thorough a broad genetic
test. In the context of cardiomyopathies, the characterization of the
family mutation helps indeed in planning surveillance and early
detecting possible complications in close relatives. This also impliescomeric and non-sarcomeric genes in patients with hypertrophic
48
Fig. 1. Distribution of identified nsSNVs. (a–b) Proportion of nsSNVs identified for (a) each analyzed gene, and for (b) each functional genic category. “Other” includes the loci coding for
lysosomal, thioredoxin reductase, anti-apoptotic andmembrane proteins. (c) Number and zygosity of DNA changes identified over 37 HCMpatients. Six caseswere found to carry a single
heterozygous nsSNV, 11 cases two heterozygous nsSNVs and 16 cases three or more nsSNVs. Four patients carried only synonymous changes, and four resulted negative to the NGS
screening. (d) Proportion of mutated patients respect to the genes' category. Dashed slices (both white and gray) stand for cases harboring at least one sarcomeric non-synonymous
variant. Light gray slices (both dashed and not dashed) represent patients not carrying any sarcomeric nsSNV, but at least one desmosomal one.
7I. Bottillo et al. / Gene xxx (2015) xxx–xxxthat relatives discovered without the familial mutation can avoid
unnecessary follow-up.
The employed high throughput sequencing technology enabled
the generation of large amounts of sequence data, and determined
the need of an accurate assessment of the identified genetic varia-
tions. The experimental characterization of all the observed DNA
changes would have support the functional and/or regulatory im-
pact of the various mutations, but it requires a long experimental
time that was impractical in our clinical setting. Likewise, co-
segregation analysis of the DNA changes within families would
have been appropriate, but it is uninformative in small pedigrees
and it is hindered by HCM incomplete penetrance and variable
expressivity.
A high number of bioinformatics solutions for the annotation,
scoring and classification of variants are currently available to address
the challenge of predicting the functional consequences of a mutation.
Our results show the relevance of incorporating integrated computa-
tional workflows to predict the biomedical impact of the various DNA
variants resulting from a NGS approach, and to identify functionally
significant or clinically actionable variants.
After the initial quality assessment of the sequencing reads, their
alignment with the reference genome, and the subsequent variant
calling, the resulting DNA changes were annotated for facilitating the
filtering and prioritization steps. Some online free sequence databases
(i.e. 1000 Genome Project, NHLBI-ESP 6500 exome projects and
dbSNP138), were helpful in the annotation process. Since all the
patients included in this study were Italian, we checked the frequency
of each variant both in 1000 Genomes Project Global and Exome
Sequencing Project Global, but also in 1000 Genomes Project
European. Based on those datasets we considered only variants
with an allele frequency ≤0.01.Please cite this article as: Bottillo, I., et al., Molecular analysis of sar
cardiomyopathy, Gene (2015), http://dx.doi.org/10.1016/j.gene.2015.11.0Sanger sequencingwas employed to rule out false positive calls from
all the filtered and prioritized DNA changes. These analyses generated a
subset of variants presenting several data interpretation challenges, but
also some interesting genotype–phenotype cues. For further delineating
the likelihood to be disease-relevant nsSNVs, we hence established a
bioinformatics framework for the assessment of each variant functional
role, based on previously reported data and in silico predictions. We
evaluated the performance of several different independently published
methods that aim to predict the functional consequences of alleles that
result in amino acid substitutions. Moreover, the impact of a sequence
variant with respect to the evolutionary conservation was derived
from genomic evolutionary rate profiling (GERP) score, phylogenetic
P-value (PhyloP) score and PhastCons score. In our hands, those
predictions aimed to hypothesize the probable impact of a particular
genetic variant on function or regulation and suggested that most
of the identified nsSNVs have the potential of being functionally
pathogenetic.
Several free online tools (i.e. SIFT, Polyphen2_HDIV, Polyphen2_HVAR,
Provean, LRT, Mutation Taster, Mutation Assessor, FATHMM,
RadialSVM, LR, CADD v1.3) were employed to assess sequence- and
structure-based features. Provean gave back a prediction score for
every input variant. Between the other tools, LRT failedmore frequently
to give a result (16 not predicted variants out of 85 different ones).
Regarding our set of DNA changes, Mutation Taster and Mutation
Assessor were the methods resulting respectively in the greater and in
the fewer number of deleterious predictions. We therefore observed
that combining multiple prediction tools provides a more even balance
between sensitivity and specificity thanmost of the individualmethods.
Besides the score-based predictions, performing molecular
modeling gave us the opportunity of visually and directly testing
the impact of amino acid substitutions on the proteins' specificcomeric and non-sarcomeric genes in patients with hypertrophic
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8 I. Bottillo et al. / Gene xxx (2015) xxx–xxxtertiary or quaternary structure. The location of a coding SNV with
respect to the surface—interior or interface of the protein
structure—could indeed influence disease manifestation.
Our NGS approach identified likely pathogenic sarcomeric variants
in 58% non-syndromic patients, consistent with previous studies that
have used both conventional genetic sequencing techniques(Marian
et al., 2001; Arad et al., 2002; Hershberger et al., 2013), and a NGS
approach in larger cohorts. In particular, in 2013 Lopes and coauthors
analyzed 223 unrelated cases for 41 sarcomeric and non-sarcomeric
cardiovascular genes and found that 121 patients (54%) carried
alterations in 9 sarcomeric genes (including ACTC1, MYPBC3, MYH6,
MYH7, MYL2, MYL3, TNNI3, TNNT2 and TPM1) (Lopes et al., 2013).
In our study we found alterations in two additional sarcomeric
loci (i.e. MYOM1 and NEBL) not analyzed by Lopes et al. (2013),
maybe explaining our slight increased rate of cases with sarcomere
gene mutations.
Inclusion of not only sarcomeric loci, but also of many different
genes implicated in cardiomyopathies, resulted in the identification of
several rare (frequency ≤0.01) DNA changes. We found that 82%
of the patients harbored at least one rare nsSNV. Our results confirm
the well-established role of MYBPC3 a major gene in the HCM
pathogenesis(Millat et al., 2010; Lopes et al., 2013), but also show that
the HCM mutational spectrum consists mainly in missense mutations.
In fact, only ~7% of the identified variants are truncating (frameshift or
nonsense SNVs), and they map preferentially in MYBPC3. This finding
suggests that MYBPC3 molecular alterations can be both amino acid
substitutions but also loss of function mutations, in contrast to the
other analyzed loci that resulted mostly affected by missense change.
We did not observe any strong mutation hot-spot, and only 8/106
nsSNVs recurred in more than one patient.
In our cohort, sarcomeric loci resulted as themost affected ones and,
among themMYBPC3,MYH6 andMYH7 showed the main proportion of
nsSNVs. These data confirm the major role of cardiac myosin binding
protein C and of myosin heavy chain 7 in hypertrophic cardiomyopathy
pathogenesis (Millat et al., 2010; Lopes et al., 2013), and following the
results by Lopes et al. (2013) clench myosin heavy chain 6 as one of
the most recently established sarcomeric HCM genes.
Eleven percent of the patients showed only sarcomere nsSNVs,
while 20% of cases harbored at least one sarcomeric nsSNV with at
least a desmosomal one. Moreover we found that 14% of the HCM
patients displayed at least one desmosomal nsSNV but no other
sarcomere change. Such a direct association of desmosomal alterations
with HCM has not been described to date. In 2013, Lopes et al. (2013)
analyzed by NGS a large cohort of HCM cases and found that 10%
of them carried nsSNVs in titin gene (TTN) only in association with
desmosomal or ion channel variants, but not other sarcomere ones.
Furthermore, mutations in the filamin C gene (FLNC) have very recently
been associatedwithHCM(Valdes-Mas et al., 2014). A proportion of our
not-sarcomeric cases could then harbor additional alterations of TTN or
FLNC, that were not included in the present NGS panel. Moreover, some
of those cases might also have alterations of genomic region that were
not covered by ourNGS panel (i.e. 3'UTR, 5'UTR, ncRNAs). Future studies
both of TTN, FLNC and of sequences regulating the cardiomyopathies
genes' expression will shed some light on rising role of desmosomes
in HCM as well as in DCM (Haas et al., 2014).
As sarcomere and desmosomes nsSNVs were the major changes
associated with HCM, and we speculate that the other non-sarcomeric
locimight have amodifying effect on HCMphenotype. As demonstrated
in a recent study, non-sarcomeric variants may indeed influence the
disease expression, outlining the complexity of HCM genetic basis
(Lopes et al., 2014). Statistical analyses performed in our cohort,
revealed that not only a higher number of nsSNVs seems to correlate
with an earlier disease onset, but also that those alterations in genes
for Ca++ homeostasis, for K+ and Na+ channels, and for cytoskeletal
proteins canmodulate HCM expression. Ion (Ca++, Na+ and K+) chan-
nel variants correlate to an earlier disease onset and to a lowermaximalPlease cite this article as: Bottillo, I., et al., Molecular analysis of sar
cardiomyopathy, Gene (2015), http://dx.doi.org/10.1016/j.gene.2015.11.0wall thickness, while changes in cytoskeletal loci correlate with
non-sustained ventricular tachycardia onset and low-grade diastolic
dysfunction. Moreover, sarcomeric nsSNVs were correlated to a lower
NYHA class. A recent study on a large HCM population, reported
that the prevalence of male sex was lower in sarcomere-positive
individuals (Lopes et al., 2014). We did not replicate this finding,
and we found a higher proportion of males respect to women in
the group of positive nsSNVs cases. The comparison of data from
familial and sporadic cases generated 3 significant correlations:
(i) the mean of the maximum wall thickness value of was lower in
the sporadic group; (ii) non-sustained ventricular tachycardia was
correlated with familial cases; (iii) the implantation of ICD resulted
to be linked to a familial framework.
We also identified 49 synonymous rare variants that might act
as phenotype modifiers. Additional studies about their function on
mRNA transcription, splicing, transport, translation or modification are
required for determining their possible non-silent role.
Among the 97 identified nsSNVs, a single variant was identified in
homozygosity (i.e. ABCC9 p.V734I in patient 21). Such a variant was al-
ready associated to a higher risk of developing precocious myocardial
infarction (Minoretti et al., 2006), but patient 21 did not show that
occurrence up to now.
Including both the non-syndromic and the syndromic cases, 25 out
of 62 genes resulted negative to the mutation screening. Between
them, there were not desmosomal loci, but four sarcomeric ones:
ACTC1, MYL3, TNNC1 and TNNI3. In line with the present results,
previous studies reported a rate of heterozygous mutated patients less
than 1% for ACTC1 (Olson et al., 2000),MYL3 (Poetter et al., 1996) and
TNNC1 (Landstrom et al., 2008). TNNI3 alterations are expected
in about 5% of HCM cases (Hershberger et al., 2013), but we did
not found any mutated patient for this gene. If a clear TNNI3 geno-
type–phenotype association exists, this discordance might be due to a
bias in patients' selection, but of course additional studies on larger
cohorts are needed to investigate this observation.
Between the 25 negative genes, therewere 16 loci already associated
with hypertrophic or dilated cardiomyopathy (ACTC1, ANKRD1, CRYAB,
DES, EYA4, GATAD1, LDB3, MYL3, MYLK2, MYOZ2, NEXN, PLN, SGCD,
TCAP, TNNC1 and TNNI3), 3 with myopathies and neuromuscular disor-
ders (EMD, FXN and TAZ), 2 with storage disorders (PRKAG2 and TTR),
one with ventricular tachycardia (CASQ2), one with arrhythmogenic
right ventricular cardiomyopathy (TMEM43), one with Noonan
syndrome (PTPN11) and one cardiovascular candidate gene (CTF1).
Six of the negative loci (ANKRD1, CRYAB, CTF1, EMD, EYA4 and FXN)
were not included in a recent study about NGS analysis of a large
cohort of HCM patients (Lopes et al., 2014).
Three patients showed syndromic HCM and the NGS analysis
allowed the confirmation of their clinical diagnosis. Patient 10 was a
60-year-old woman with apparently isolated non-obstructive HCM
featuring a maximum left ventricular wall thickness of 18 mm.
Subsequently, she resulted heterozygous carrier of the p.N215S
mutation in GLA gene, responsible of the X-linked recessive Fabry
disease. This mutation was previously associated to a cardiac variant
of the disease by Eng et al. (1993) and by Davies et al. (1993), and our
data confirm this genotype–phenotype association. Patient 24 was a
6-year-old girl originally ascertained for the clinical suspect of Cantù
syndrome, a syndromic form of early-onset HCM also featuring
coarse face, hirsutism, persistence of fetal circulation, overgrowth
of prenatal onset andmild bone dysplasia, whichwas recently associated
with specific ABCC9 mutations (van Bon et al., 2012). Accordingly, we
found the recurrent heterozygous ABCC9 p.R1154W mutation, which
subsequently resulted de novo (Harakalova et al., 2012; van Bon et al.,
2012). Finally, patient 27 showing some intellectual impairment and
severe cardiac disease requiring heart transplant and limb weakness,
harbored the novel p.F151fs mutation in LAMP2, the gene causing
Danon's disease, an X-linked dominant disorder predominantly affecting
cardiac muscle (Nishino et al., 2000).comeric and non-sarcomeric genes in patients with hypertrophic
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By the use of NGS technology and in view of the genetic overlap
between different types of cardiomyopathies, we developed a molecu-
lar test suitable for a broad series of both non-syndromic and syndromic
affected patients. Moreover, despite the large amount of data coming
out from an NGS protocol, we delineated a prompt informatic pipeline
for the prioritization of the most likely pathogenetic variants in a
clinical context.
Thanks to the possibility of analyzing many sarcomeric and non-
sarcomeric loci, the conducted genotype–phenotype correlations repre-
sent a starting point for expanding the present results to larger cohorts
and for delineating the contribution of each analyzed gene in the onset
and clinical variability of HCM. In the future indeed, a broad range of
molecular causes (i.e. desmosomal or other non-sarcomeric alterations)
and environmental factors will need to be investigated in wider
populations of sporadic and familial cases.
In conclusion, our results enlarge the mutational spectrum of
hypertrophic cardiomyopathy patients with the intent of contributing
to the definition of a molecular paradigm for explaining the clinical
HCM diversity.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gene.2015.11.048.
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